Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links.

BACKGROUND: Epidemiological data suggest that lower urinary tract symptoms (LUTSs) may be associated with metabolic syndrome (MetS). Inflammation has been proposed as a candidate mechanism at the crossroad between these two clinical entities. The aim of this review article is to evaluate the role of MetS-induced inflammation in the pathogenesis and progression of LUTS.
METHODS: A systematic review was conducted using the keywords 'metabolic syndrome and lower urinary tract symptoms' within the title search engines including PubMed, Web of Science and the Cochrane Library for relevant research work published between 2000 and January 2015. The obtained literature was reviewed by the primary author (QH) and was assessed for eligibility and standard level of evidence.
RESULTS: Total of 52 articles met the eligibility criteria. On the basis of database search during the past 15 years and our systematic review of prospective and retrospective cohorts, case-control trials, observational studies and animal data identified a possible link between MetS-induced inflammation and LUTS including BPH, bladder outlet obstruction, overactive bladder, urinary incontinence and other possible urinary tract abnormalities.
CONCLUSIONS: There is convincing evidence to suggest that MetS and inflammation could be important contributors to LUTS in men, particularly in the development of BPH. However, the role of MetS-induced inflammation remains unclear in overactive bladder, urinary incontinence and etiology of LUTS progression.

1. Introduction

In recent decades, there has been a dramatic increase in obesity around the world and nearly half of the elderly population in the United States will be obese by 2030[1]. It can be predicted that in the aging baby boomer population, a dramatic rise in the incidence of obesity-related diseases (including cardiovascular and cerebrovascular diseases) will occur, which will have a significant impact on the American economy and healthcare system[2,3]. There is growing evidence that obesity may be one of the key etiological factor of metabolic syndrome-induced inflammation and other severe health problems[3-6]. Metabolic syndrome (MetS) is a term proposed to encompass a variety of cardiovascular and metabolic risk factors, such as visceral obesity (increasing body mass and waist circumference), hypertension, hyperglycemia, low levels of high-density lipoprotein cholesterol (HDL-C) and hypertriglyceridemia, in an effort to identify a diagnostic category able to predict cardiovascular-metabolic complications[2,4-6]. Although the correlations between the aforementioned disorders and MetS have been widely accepted, the patho-genetic links still needs to be elucidated.

A significant amount of epidemiological evidence indicates a possible association between MetS and Lower Urinary Tract Symptoms (LUTS). LUTS used to be generally considered a hallmark of benign prostatic hyperplasia (BPH) and its related bladder dysfunction, resulting from an intertwined contribution of static (prostate enlargement), dynamic (α-adrenergic receptor-mediated muscle tension) and inflammatory determinants[7,8]. Historically, male LUTS was thought to be merely related to benign prostatic hyperplasia, however, a simplistic causal relationship linking prostatic overgrowth, progressive urethral obstruction, urinary retention and LUTS, has been challenged, based on the incomplete overlap of prostatic enlargement with symptoms[8-10]. In fact, investigations into the relationships between LUTS, prostate volume and urodynamic parameters failed to identify a causative relationship between parameters of BPH severity and symptoms, suggesting that other factors may interfere in determining LUTS. Now LUTS is recognized to be a non–sex-specific, non–organ-specific and global term that encompasses all urinary symptoms, including storage, voiding, and post-micturition symptoms with a significant negative impact on patients’ quality of life[11].

Previous epidemiological studies and meta-analysis have already demonstrated an association between LUTS and obesity/MetS[12-15], and also the pathogenesis has been attributed to systemic inflammation and oxidative stress associated with MetS[16-18]. Chronic inflammation has been proposed as a candidate mechanism at the crossroad between BPH/LUTS and MetS. In fact, MetS can broadly be considered a systemic inflammatory state and a chronic inflammation-driven tissue remodeling, and overgrowth is recognized to have a causative role in BPH/LUTS[19]. Mets-induced pro-inflammation states have been reported in female overactive bladder, urinary tract infection and urinary incontinence, although there is limited data to support such assertions[20-22]. The aim of the present review is to evaluate recent literature regarding associations between MetS-induced inflammation and various disorders of the lower urinary tract. Through the database search performed on National Center for Biotechnology Information (NCBI) PubMed, Web of Science, and the Cochrane Library for relevant research work published between 2000 and January 2015 combining the following terms: metabolic syndrome, inflammation, lower urinary tract symptoms and/or benign prostatic hyperplasia, urinary incontinence, overactive bladder, nocturia. A list of records involving human subjects and studies involving animals and cell culture were assessed for eligibility and standard level of evidence (Supplemental Figure 1).

2. MetS-induced inflammation associated with BPH/Bladder outlet obstruction

Several studies have demonstrated that components of MetS such as type 2 diabetes (T2DM), hypertension, hyperinsulinemia and dyslipidemia directly correlate with pro-inflammatory state, oxidative stress and pro-fibrosis[23,24]. Biomarker studies on MetS have shown to be associated with elevated levels of C-reactive protein (CRP), a nonspecific marker of inflammation, as well as pro-inflammatory cytokines interleukin (IL)-1, IL-6, and tumor necrosis factor-α (TNF-α)[25-27]. One etiology may be the presence of inflamed adipose tissue. Obesity induces adipose cell enlargement and chemokine release, leading to macrophage infiltration of adipose tissue[23,28]. Mounting evidence suggests the ability of IL-8 to stimulate prostatic growth, and a significant and stepwise correlation between various MetS components and seminal IL-8 (sIL-8) has been proposed as a surrogate marker of prostate inflammation[27,29,30]. IL-8 is a pro-inflammatory chemokine secreted by several cell types that contributes to inflammation by acting in concert with IL-1β and IL-6. Of all kinds of cytokines and chemokines, sIL-8 seems to be the most reliable and predictive surrogate marker of prostatitis[27,29]. Higher IL-8 levels have been reported in the expressed prostatic secretions of subjects with BPH, bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)[31,32]. IL-8 has been shown to be actively involved in BPH-associated chronic inflammation and mediates epithelial and stromal cell proliferation[33-35]. In clinical BPH-prostate tissue studies, epithelial and stromal cells were analyzed to secrete IL-8 actively in response to various stimuli, including the pro-inflammatory cytokines interferon (IFN) γ and IL-17, which are produced by prostate-infiltrating Th1 and Th17 cells, respectively[36,37]. Human stromal prostatic cells actively contribute to the organ-specific inflammatory process by acting as targets of bacterial or viral toll-like receptors agonists and as antigen-presenting cells capable of activating antigen-specific CD4+ T cells. In BPH, toll-like receptor activation leads to the production of pro-inflammatory cytokines (IL-6) and chemokines (IL-8 and CXCL10) capable of recruiting CXCR1 and CXCR2-positive leukocytes and CD15+ neutrophils[35]. Moreover, secretion of IL-8 has been shown to induce the expression of fibroblast growth factor (FGF)-2, a potent stromal and epithelial growth factor that promotes abnormal proliferation of prostatic cells[38]. In addition, CXCL5, CXCL1, CXCL6, and CXCL12-induced proliferative responses have been observed in both epithelial and stromal prostate cells in vitro[38]. CXC-type chemokines, which comprise inflammatory proteins and known to be highly expressed in the aging prostate, can efficiently and completely mediate myofibroblast phenotype conversion thereby promoting fibrotic changes in prostate tissue architecture associated with the development and progression of lower urinary tract dysfunctions[39]. Our previous studies conducted in mice showed that continuous consumption of high-fat diet (HFD) induces oxidative stress and inflammation in the mouse prostate. High-fat diet intake increases expression of IL-6, PKC, and p-Akt (Ser473) in the prostate, followed by activation of Stat-3 and NF-κB/p65 transcription factors, and their sustained interaction is associated with increased prostatic inflammation[40,41]. Moreover, Vignozzi and colleagues have shown that rabbits exposed to high-fat diets resulted in marked decrease in the mRNA expression of several pro-inflammatory cytokines (IL8, IL6, IL1β, and TNFα), T lymphocyte (CD4, CD8, T-bet, Gata3, and RORγt), macrophage (TLR2, TLR4, and STAMP2), neutrophil (lactoferrin), inflammation (COX2 and RAGE) and fibrosis/myofibroblast activation (TGFβ, SM22α, αSMA, RhoA, and ROCK1/ROCK2) markers after Tadalafil treatment[42,43].

The majority of observational clinical studies suggest that inflammation is linked to the development of BPH and LUTS. Clinical BPH/LUTS specimens contain about 70% T lymphocytes, 15% B cells, and 15% macrophages, as well as a smaller subpopulation of mast cells. Most of the patients had inflammatory cells infiltrating BPH tissues: 81% had T-lymphocytes markers (CD3), 52% had B-lymphocytes markers (CD20), and 82% had macrophages markers (CD163)[40]. In prostate tissue, T-lymphocytes actively secrete a diverse array of chemokines into the surrounding microenvironment. Immuno-histochemical studies examining the histopathology of BPH have reported the presence of inflammatory infiltrates containing leucocytes associated with acute and/or chronic inflammation[44,45]. Neutrophilic or lymphocytic infiltrates were identified in 90% of transurethral resections of the prostate (TURP) specimens from 80 patients with BPH/LUTS but with no history of prostatitis or prostatic infection[46,47]. Patients with chronic inflammatory infiltrate had larger prostate volumes and were more likely to experience clinical progression and acute urinary retention than those with no evidence of inflammation. In another study[48], BPH was found in 93 of 167 patients who underwent autopsy; 75% of these glands contained inflammatory infiltrates (predominantly associated with chronic inflammation) compared with 50% of glands without signs of BPH and 55% of glands with evidence of cancer. The level of inflammation has been directly correlated with prostatic volume and IPSS. Prostatic inflammation was strongly associated with LUTS severity, and patients with chronic inflammation had higher IPSS than those without inflammation (21 versus 12, respectively; P = 0.02). Moreover, prostate volume was significantly higher in patients with more pronounced inflammation (77 versus 62 mL; P = 0.002). Patients in the highly-inflamed group more commonly underwent open prostatectomy than those with less pronounced inflammation. This finding may also be related to the association between prostate volume and chronic intraprostatic inflammation. Patients included in the highly-inflamed group more commonly underwent TRUS-guided prostate biopsy than those with less pronounced inflammation (37.6 versus 23.9%; P < 0.02)[44]. Similar conclusions have been reported in other large clinical studies[49-51]. In a small prospective trial, chronic inflammation was shown to induce fibrotic changes in 30 peri-urethral prostate tissues from retro-pubic radical prostatectomy. Fibrosis in this region is alleged to promote urethral stiffness and LUTS[52]. A comprehensive summary and the evidence level of these studies are shown in table 1.

Table 1

Studies on MetS-induced inflammation associated with benign prostatic hyperplasia/ bladder outlet obstruction.

Author/Year	Study	Country	Samplesize	Biomarkers	Comments	Evidencelevel
Fibbi B; 2010[27]	BS	Italy	-	IL-8, Th1,Th17	Prostate growth-promotingchemokine IL-8, induced in BPHstromal cells by a combination ofTh1 and Th17 cell-derivedinflammatory cytokines.	d
Penna G; 2007[29]	Cohort	Italy	83 men	IL-1α, IL-1β,IL-6, 10,IL12p70,CCL1,3,4,CXCL8/IL-8	IL-8 appears to be the most reliableand predictive surrogate marker todiagnose prostate inflammatoryconditions.	2b
HochreiterWW; 2000 [31]	Cohort	USA	63 men	IL-8, ENA-78	IL-8 and ENA-78 were elevated inthe prostatic secretions of men.	2b
Liu, L; 2009 [32]	Cohort	China	44 men	IL-8	IL-8 expressed prostatic secretioncan serve as a reliable biomarker inidentifying BPH with chronicprostatitis from simple BPH.	2b
Lotti F; 2014[33]	Cohort	Italy	171 men	sIL8,	Insulin levels increased as afunction of MetS components (P <0.0001). MetS is positivelyassociated with prostateenlargement, biochemical (sIL8)and ultrasound-derived signs ofprostate inflammation.	2b
Giri D; 2001 [38]	BS	USA	-	IL-8, FGF2	IL-8 can induce FGF2 andpromote abnormal proliferation ofthe prostatic transition zone.	d
Gharaee-Kermani M;2012 [39]	BS	USA	-	TGF-β1,CXCL5,CXCL8, orCXCL12	Prostate stromal fibroblasts areinduced to express collagen 1 and3 and αSMA gene transcripts andproteins to undergo completefunctional myofibroblast pheno-conversion in response to CXC-type chemokines, even in theabsence of exogenous TGF-β1.	d
Shankar; 2012[40,41]	BS	USA	C57BL/6mice	IL-1ß, IL-6,IL-17, TNFα,NF-κB, Stat-3, Akt,PDK1, PKCε	High-Fat Diet activates Stat-3 and NF-κB/p65 in the prostate,and their interaction is associatedwith increased inflammation in theprostate.	d
Vignozzi L;2014 [42,43]	BS	Italy	rabbits	GLUT4 ,IL-6,RhoA/ROCK	Tadalafil dosing reducedRhoA/ROCK signaling and smoothmuscle over-activity in ananimal model of MetS-associated bladder alterations.	d
Robert G;2009 [44]	RS	France	282patients	CD3, CD4,CD8, CD2,CD163	Prostate enlargement due tochronic inflammatory process maylead to BPH progression.	1b
DelongchampsNB; 2008 [45]	RS	USA	167prostates	-	Chronic inflammation was acommon finding in autopsiedprostates.	1b
McConnell JD;2003 [46]	RCT	USA	3047men	-	Combination therapy andfinasteride alone reduce long-termrisk of acute urinary retention andthe need for invasive therapy.	1a
Zlotta AR;2014 [48]	Cohort	Canada	320prostateglands	-	Chronic inflammation in >70%of men on autopsy. Increasedchronic inflammation wasassociated with more BPH.	1b
Mishra VC;2007 [50]	RS	UK	406patients	-	70% of men with urinary retentionhad acute and/or chronicintraprostatic inflammation (ACI),vs 45% of those with LUTS (P <0.001). The association of TURPfor retention with ACI was strongerthan that with prostate weight.	2b
Nickel JC;2008 [51]	RCT	Canada	8224men	-	Weak correlations were foundbetween average and maximumchronic inflammation and IPSSvariables.	1a
Cantiello F,2013 [52]	Cohort	Italy	30patients	-	Patients experiencing prostate-related LUTS could benefit fromanti-inflammatory therapies, usedalone or combined with thecurrently prescribed regimen.	2b

BS, basic study; RCT, random control trial; RS, retrospective study

3. MetS-induced inflammation associated with Overactive bladder/Urinary incontinence

Overactive bladder (OAB) is the other major clinical manifestation of LUTS, typically characterized by urinary urgency, frequency, and urge incontinence adversely affecting patients’ quality of life having an increasing prevalence with age[53]. It was now recognized that chronic low-level inflammation and activation of the immune system are involved in the pathogenesis of obesity-related insulin resistance[54]. Insulin resistance caused by obesity is a significant component of MetS and is regarded as a pro-inflammatory state. Tissue inflammation results in tissue fibrosis, which is supposed to represent an inflammation-initiated, aberrant wound-healing process characterized by myofibroblast accumulation, collagen deposition, extracellular matrix (ECM) remodeling, and increased tissue stiffness[39,55-57]. A few studies have investigated possible associations between MetS-induced inflammation and overactive bladder or urinary incontinence (UI). Some investigators have studied the role of urinary cytokines in patients with OAB[58,59]. Tyagi et al. have shown 10-fold increase in the levels of monocyte chemotactic protein-1 (MCP-1) and CD40 ligand , whereas 5-fold elevations were detected in macrophage inflammatory protein (MIP-1β), IL-12p70/p40, IL-5, epidermal growth factor (EGF), and growth-related oncogene GRO-α compared to controls[60]. Significant 3-fold elevation was also noticed in the urine levels of sIL-2Rα, and IL-10 in OAB patients. Another study demonstrated that C-reactive protein (CRP) was significantly higher in women with OAB associated with urgency incontinence, (n = 30, 0.12 mg/dl) as compared to women with bladder oversensitivity (n = 68, 0.075 mg/dl, P = 0.008) and nerve growth factor (NGF), IL-1β, IL-6, IL-8, and TNF-α levels were higher than the control group[58,59]. Further analysis revealed that body mass index and maximum flow rate were two independent factors that affected CRP levels. The area under the receiver-operating characteristic curve for using CRP to predict OAB wet was 0.55, and the most predictive cutoff point for CRP was 0.15 mg/dl (sensitivity 43.5%; specificity 72.7%). Chung and colleges[61] conducted a similar study and found that the patients of OAB associated with urgency incontinence had higher serum CRP level than patients without urge incontinence. Indications of tissue remodeling and inflammation-induced fibrosis have been reported in several animal studies. Lenis et al. found that vaginal distention up-regulated urethral expression of CCL7 immediately after injury in virgin and postpartum rats[62]. Hypoxia inducible factor-1α and vascular endothelial growth factor were up-regulated only in virgin rats immediately after vaginal distention. CD191 expression was immediately up-regulated in postpartum rats without vaginal distention compared to virgin rats without vaginal distention. CD195 was up-regulated in virgin rats 3 days after vaginal distention compared to virgin rats without vaginal distention. CD193 and CXCR4 showed delayed up-regulation in virgin rats 7 days after vaginal distention. CXCL12 was up-regulated in virgin rats 3 days after vaginal distention compared to successive vaginal distention. IL-8 and CD192 exhibited no differential expression. Remodeling of urethral connective tissue has also been detected in rodent stress urinary incontinence (SUI) models[63,64]. Inflammatory and fibrosis markers, TGF-β1, fibronectin and type I collagen expressions were observed to be significantly increased 6 months post-surgical induction of OAB in a rat model[65]. Recently, increasing emphasis has been focused on the role of neurotrophines, including nerve growth factors and brain-derived neurotrophic factors (BDNF) to evaluate OAB and bladder dysfunction[66,67]. Elevated levels of NGF or BDNF have been associated with OAB and other conditions, including urinary tract infection, stones and tumors[68].

Numerous clinical studies have shown association between the components of MetS and OAB[62,64,66,67]. The onset of OAB is significantly associated with obesity[69]. Link et al. investigated for an association between visceral obesity (waist circumference, hip circumference, waist-to-hip ratio and body mass index) with OAB (urinary frequency and urgency) and whether the association varies by gender or age[70], and noted distinct patterns by gender for the association of various adiposity measures with OAB. The prevalence of OAB increased as waist (OR adjusted for other confounders 1.10/10cm increase) or hip circumference (OR 1.12/10cm increase) or body mass index (OR 1.03/kg/m2 increase) increased in women; whereas in men the prevalence of OAB decreased as adiposity increased (OR 0.65/10cm increase in waist circumference, OR 0.71/10 cm increase in hip circumference and OR 0.87/kg/m2 in body mass index) but only to a certain point (waist circumference 100cm, hip circumference 115 cm and body mass index 27.5 kg/m2). At that point the prevalence of OAB increased with increasing adiposity (OR 1.19/10cm increase in waist circumference, OR 1.16/10cm increase in hip circumference and OR 1.08/kg/m2 in body mass index), suggesting gender-specific relationship between adiposity and OAB. In our previous meta-analysis which combined 12 BPH/UI/LUTS studies[71], a positive association was observed between waist circumference (WC) and LUTS at an OR of 1.49, (95% CI: 1.34–1.64) and a 10 cm increase in waist circumference was associated with a statistically-significant 2.5% increase in the risk of LUTS; when separated by gender, that is 1.8% increase in LUTS risk in male and a 2.8% increase in female. A cross-sectional study from Taiwan assessed 371 women with the Incontinence-Quality of Life (I-QOL) questionnaire, and noted that stress urinary incontinence (SUI) was the most frequent subtype reported (28.6%), followed by mixed (24.5%) and urge (16.2%) incontinence and obesity (OR 3.38, 95% CI 1.94–6.98) and postmenstrual status (OR 2.17, 95% CI 1.35–3.50) were found to be risk factors of incontinence (P < 0.001)[72]. Hakki Uzun et al. demonstrated that serum insulin levels were higher in female patients with OAB (11.5 ± 6.2 μU/mL) relative to controls (6.4 ± 2.1 μU/mL, P=0.036). Insulin resistance was significantly higher in the OAB group, 2.86 (0.76 to 17.04) in comparison to controls, (1.32; 0.67 to 224, P=0.018). High-density lipoprotein cholesterol levels (HDL-c) were significantly lower in females with OAB[73]. There is lack of strong evidence and inconclusiveness to estimate the potential association between MetS and OAB/UI. A comprehensive summary and the evidence level of these studies are shown in table 2.

Table 2

Studies on MetS-induced inflammation associated with overactive bladder/urinary incontinence.

Author/Year	Study	Country	Samplesize	Biomarkers	Comments	Evidencelevel
Hsiao S-M;2012 [59]	Cohort	China	197 women	CRP	High serum CRP levels were foundin women with OAB wet, and wasrelated to lower maximum urinaryflow rates and higher body massindices in non-SUI LUTD.	2b
Tyagi P; 2010[60]	Cohort	USA	17 womenmidstreamurine	MCP-1, IL-12p70/p40,IL-5, EGF	The presence of elevated levelsin urine of inflammatory biomarkersinvolved in inflammation and tissuerepair suggests a role forinflammation in OAB.	3b
Chung SD;2011 [61]	Cohort	China	70 women	NGF, CRP	Serum CRP levels weresignificantly higher in subjectswith OAB, chronic inflammationassociated with OAB or IC/BPS.	3b
Lenis AT;2013 [62]	BS	USA	72 rats	CCL7, CXCL12, CD191,CD193 andCXCR4	Pregnancy and parturition in ratscontributes to the expression ofchemokines and receptors aftervaginal distention.	d
Chen H-Y;2013 [63,64]	BS	China	18 mice	LOX	SUI following vaginal traumainvolves over-expression of LOXand decrease synthesis ofextracellular matrix components orincreased proteolysis in theurethra.	d
Wang L-W;2014 [66]	Cohort	China	90 women	BDNF, NGF	Urinary BDNF/Cr levels areelevated in women with OAB andare significantly associated withsymptom severity.	2b
Dallosso H;2003 [69]	Cohort	UK	7,046women	-	Causal associations with obesity,smoking and carbonated drinks areconfirmed for bladder disordersassociated with incontinence, andadditional associations with diet aresuggested.	1b
Link CL; 2011[70]	Cohort	USA	5,503participants	-	Relationship between adiposity andoveractive bladder varies bygender.	1b
He Q; 2014 [71]	MA	USA	83,304cases	-	Large waist circumference isassociated with increased risk ofLUTS. A 10 cm increase in WCcorresponded to a 1.8% increase inLUTS risk in male and a 2.8% riskin female.	1b
Tsai Y-C;2009 [72]	Cohort	China	551 women		Obesity (OR 3.38, 95% CI 1.94-6.98) and postmenstrual status(OR 2.17, 95% CI 1.35-3.50) werefound to be risk factors ofincontinence (P < 0.001).	2b
Uzun H; 2012[73]	Cohort	Turkey	122patients	-	Insulin resistance can beassociated to overactivebladder and may play significantrole in pathogenesis.	2b

BS, basic study; MA, meta-analysis

4. Inflammation, infection and their association with LUTS

Inflammation and inflammatory damage to the lower urinary tract may result from bacterial prostatitis and urinary tract infection (UTI). Several studies have documented an association between prostatitis/UTI and subsequent development of LUTS. Data from the Health Professionals Follow-up Study showed a significant association between a history of gonorrheal infection or young-onset (aged <30 years) prostatitis and later development of LUTS[74]. Combined data from five studies involving a total of 10,617 men suggest that men reporting a history of prostatitis have a substantially increased risk of developing BPH, LUTS, and prostate cancer[75]. UTIs are also associated with male lower urinary tract dysfunction (LUTD). In a study of 208 patients with bacteriuria, 54% were diagnosed with UTIs and these patients demonstrated voiding dysfunction manifested by higher rates of dysuria (P = 0.0001), urgency (P = 0.0001), and frequency (P = 0.0001)[76]. Lee et al. developed an animal model of bacterial uropathogenic E. coli—1677 induced isolated prostatic inflammation and examined the effect of prostatic inflammation on voiding behavior in adult C57BL/6J mice[77]. Mice with prostatic inflammation showed significantly increased voiding frequency and decreased volume per void, compared to mice instilled with saline. Linked analysis of voiding frequency and voided volumes revealed an overwhelming preponderance of high frequency, low volume voiding in mice with prostatic inflammation, suggesting that prostatic inflammation may be causal for symptoms of urinary frequency and nocturia. Another study demonstrated an increase in lipocalin 2 (LCN2) expression in the bladder, ureters, and kidneys of mice with Escherichia coli strain H9049. LCN2 is an innate immunity protein that binds to bacterial siderophores and starves them for iron, thus representing a novel host defense mechanism to infection. LCN2 was protective with higher bacterial numbers retrieved from bladders of Lcn2-deficient mice than from wild-type mice infected with the LCN2-sensitive E. coli. This study further demonstrates that a human cohort of women with recurrent E. coli UTIs, urine LCN2 levels are associated with UTI episodes and with evidence of bacteriuria[78]. Other recent studies have suggested that MetS-induced inflammation and altered lipid metabolism were common occurrence during bladder and kidney stone formation which might result in increasing incidence of LUTS[79-81].

5. Limitation of the work

This review has certain limitations. Definitions of LUTS is not uniform in the literature and this impedes proper comparisons. This review may have a publication bias in the choice of the reviewed studies. Although an attempt was made to retrieve and review all existing published data, but some studies may have been overlooked, and adequate emphasis may not have not been provided to some study designs.

6. Conclusion and future direction

A number of studies support MetS as a complex disorder consisting of numerous interrelated pathophysiologic entities including obesity, dyslipidemia, hyperglycemia/IR, all of which are thought to promote endothelial and smooth muscle dysfunction, which may contribute to the pathogenesis and progression of various conditions associated with LUTS. There is sufficient evidence to suggest that inflammation is an important predictor of LUTS in men, particularly in BPH and bladder outlet obstruction, while its association remains unclear in OAB/UI and other lower urinary tract disorders. Knowledge of these associations may assist urologists in their clinical management of patients with LUTS. In studies involving academic and translational medicine, a better understanding of the inflammatory pathways in MetS, might be helpful to identify and develop new forms of treatment for LUTS-associated disorders.